Bridgehead Completes Due Diligence Assignment for Global Private Equity Company, Riverside

20th February 2012  Bridgehead International has recently completed a substantial commercial due diligence assignment for the global private equity firm, The Riverside Company.  The target was a European pharmaceutical company with both marketed assets and a strong R&D pipeline.

William Jaworski, Senior Associate at Riverside commented, “Thanks in part to the solid advice, analysis and pharmaceutical industry experience demonstrated by Bridgehead, we secured a promising investment in a fast-growing European pharmaceutical company. The combination of Bridgehead’s in-depth understanding of the sector, coupled with their strong reporting and analytical skills, gave us everything we needed to know about the target’s product portfolio and its commercial capabilities and helped us find peace of mind regarding the strength of its development pipeline. We’ve been delighted with Bridgehead; the work was carried out on time, on budget and to an excellent standard. We would certainly use Bridgehead again for any future pharmaceutical consultancy work.”

Timothy Fitzgerald, CEO of Bridgehead International added, ‘Bridgehead’s expert team was able to provide a rapid, in depth assessment of the target’s business, ranging from financial projections, commercialisation strategy, market access and pricing through to the research and development portfolio.   It is very satisfying to see that our advisory work has contributed to this investment and we wish the company and its investors every success for the future’.

Notes for Editors:

The Riverside Company

The Riverside Company is a global private equity firm focused on acquiring growing businesses valued at up to $200 million (€200 million in Europe). Since its founding in 1988, Riverside has invested in more than 275 transactions. The firm’s international portfolio includes more than 75 companies, and it has $3.2 billion/€2.5 billion in assets under management.

About Bridgehead International Ltd

Bridgehead is a leading strategic healthcare consultancy group, providing a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain.

Bridgehead's mission is to work with commercial organisations, government agencies and the investment community to ensure that:

• Companies have the funding, structure and strategic focus to deliver high levels of innovation and financial return
• Patients have rapid and broad access to new innovative medicines, medical devices and diagnostic tools, particularly in areas of high unmet need.

With over 50 consultants and 60 associates in Europe, North America and Asia, Bridgehead provides a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modelling and intellectual property skills and experience. 

Bridgehead is globally recognised for its expertise in:

• Market access strategy
• Pricing and reimbursement strategy
• Health economics and health technology assessment
• Opportunity evaluation
• Transaction support.

In 2007 and 2011, Bridgehead was honoured with The Queen’s Award for Enterprise, for outstanding achievement in international trade. The Queen’s Award for Enterprise is the highest honour that can be bestowed upon a UK company and is the UK’s top award for business performance.

In 2009, Bridgehead was voted UK Strategic Advisor of the Year – Healthcare, in the ACQ Finance Magazine’s Global Awards.

For more information about Bridgehead International, please see http://www.bridgehead.com

Contacts at Bridgehead International:

Feb 20, 2012